Necip İLHAN, Hüseyin ÇELİKER, Dilara KAMAN, Kadir ATEŞ

eNOS Glu298Asp Polymorphism and Endothelial Dysfunction in Patients with and without End-stage Renal Disease

Background: Chronic kidney diseases are known to influence nitric oxide metabolites (NOx) and asymmetric dimethylarginine (ADMA), though the exact mechanism is still poorly understood. Aims: The purpose of the present study was to examine eNOS Glu298Asp gene polymorphism, plasma NOx and ADMA concentration in subjects with and without End-stage Renal Disease. Study Design: Case-control study. Methods: In this study, genotype distributions of Glu- 298Asp in exon 7 of the eNOS gene polymorphisms in 130 hemodialysis and 64 peritoneal dialysis patients were compared with 92 controls. NOx was measured by using the Griess reaction while arginine, ADMA and SDMA measurements were performed by HPLC. Genotyping for eNOS Glu298Asp polymorphism was detected with the polymerase chain reaction and/or polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Results: When the genotype frequencies of TT and GT genes were compared between both groups, there was no detected statistically important difference, eventhough a TT genotype frequency was 27 (20.8%) versus 17 (26.6%), GT heterozygote genotype frequency was 52 (40%) versus 22 (34.4%), and GG homozygote genotype frequency was 51 (39.2%) versus 25 (39.1%), respectively (p>0.05). NOx, SDMA and ADMA concentrations were significantly elevated in subjects with hemodialysis patients as compared to their corresponding controls. Whereas nitrite was found to be significantly decreased in the patient with peritoneal dialysis. Conclusion: Not observed any connection between the Glu298Asp polymorphism in the eNOS gene and end-stage Renal Diseases in our study population under different dialysis treatments. However, higher ADMA and SDMA concentrations in subjects with ESRD support the existing hypothesis that NOx overproduction affects endothelial dysfunction. Thus, the reduction of ADMA and SDMA concentrations might play a protective role in ESRD patients.

PDF

___

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009;58:1624-8. [CrossRef]
Förstermann U. Oxidative stress in vascular disease: causes, de- fense mechanisms and potential therapies. Nat Clin Pract Car- diovasc Med 2008;5:338-49. [CrossRef]
Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-7. [CrossRef]
Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Nephrol 1995;44:1135-8.
Daschner M, Lenhartz H, Botticher D, Schaefer F, Wollschlager M, Mehls O, et al. Influence of dialysis on plasma lipid peroxidation prod- ucts and antioxidant levels. Kidney Int 1996;50:1268-72. [CrossRef]
Paradossi U, Ciofini E, Clerico A, Botto N, Biagini A, Colom- bo MG. Endothelial function and carotid intimamedia thick- ness in young healthy subjects among endothelial nitric ox- ide synthase Glu298Asp and T-786C polymorphisms. Stroke 2004;35:1305-9. [CrossRef]
Naber CK, Baumgart D, Altmann C, Siffert W, Erbel R, Heusch G. eNOS 894T allele and coronary blood flow at rest and during adenosineinduced hyperemia. Am J Physiol Heart Circ Physiol 2001;281:1908-12.
Hsu CN, Huang LT, Lau YT, Lin CY, Tain YL. The combined ratios of L-arginine and asymmetric and symmetric dimethylar- ginine as biomarkers in spontaneously hypertensive rats. Transl Res 2012;159:90-8. [CrossRef]
Busch M, Fleck C, Wolf G, Stein G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology? Amino Acids 2006;30:225-32. [CrossRef]
Lu TM, Chung MY, Lin CC, Hsu CP, Lin SJ. Asymmetric di- methylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:1566-72. [CrossRef]
Szlachcic A, Krzysiek-Maczka G, Pajdo R, Targosz A, Magi- erowski M, Jasnos K, et al. The Impact of Asymmetric Dimeth- ylarginine (ADMA), the Endogenous Nitric Oxide (NO) Syn- thase Inhibitor, to the Pathogenesis of Gastric Mucosal Damage. Curr Pharm Des 2013;19:90-7. [CrossRef]
Young JM, Terrin N, Wang X, Greene T, Beck GJ, Kusek JW, et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1115-20. [CrossRef]
Tatematsu S, Wakino S, Kanda T, Homma K, Yoshioka K, Hasegawa K, et al. Role of nitric oxide-producing and -degrad- ing pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2007;18:741-9. [CrossRef]
Kerkeni M, Letaief A, Achour A, Miled A, Trivin F, Maaroufi K. Endothelial nitric oxide synthetase, methylenetetrahydrofolate reductase polymorphisms, and cardiovascular complications in Tunisian patients with nondiabetic renal disease. Clin Biochem 2009;42:958-64. [CrossRef]
Thaha M, Pranawa, Yogiantoro M, Sutjipto, Sunarjo, Tani- moto M, et al. Association of endothelial nitric oxide synthase Glu298Asp polymorphism with end-stage renal disease. Clin Nephrol 2008;70:144-54. [CrossRef]
Santos KG, Crispim D, Canani LH, Ferrugem PT, Gross JL, Roisenberg I. Association of eNOS gene polymorphisms with renal disease in Caucasians with type 2 diabetes. Diabetes Res Clin Pract 2011;91:353-62. [CrossRef]
Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, et al. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008;51:184-91. [CrossRef]
Zhou TB, Yin SS. Association of endothelial nitric oxide syn
thase Glu298Asp gene polymorphism with the risk of end-stage renal disease. Ren Fail 2013;35:573-8. [CrossRef]
Zhou TB, Xu HL, Yin SS. Association between endothelial nitric oxide synthase Glu298Asp gene polymorphism and diabetic ne- phropathy susceptibility. Ren Fail 2013;35:173-8. [CrossRef]
Yun Z, Yu-Ping Y, Zong-Wu T, Yang S, Fang Y, Fang S. Asso- ciation of endothelial nitric oxide synthase gene polymorphisms with end-stage renal disease: a systematic review and meta-anal- ysis. Ren Fail 2014;36:987-93. [CrossRef]
Afrasyap L, Ozturk G. NO level and endothelial NO synthase gene polymorphism (Glu298Asp) in the patients with coronary artery disease from the Turkish population. Acta Biochim Bio- phys Sin (Shanghai) 2004;36:661-6. [CrossRef]
Granger DL, Taintor RR, Boockvar KS, Hibbs JB Jr. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol 1999;268:142-51. [CrossRef]
Aldámiz-Echevarría L, Andrade F. Asymmetric Dimethylargi- nine, Endothelial Dysfunction and Renal Disease. Int J Mol Sci 2012;13:11288-311. [CrossRef]
Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004;15:77-80. [CrossRef]
Tang FY, Liu FY, Xie XW. Association of angiotensin-convert- ing enzyme and endothelial Nitric Oxide synthase gene poly- morphisms with vascular disease in ESRD patients in a Chinese population. Mol Cell Biochem 2008;319:33-9. [CrossRef]
Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999;19:1168-72. [CrossRef]
Rossi GP, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hy- pertensive patients. J Am Coll Cardiol 2003;19:938-45. [CrossRef]
Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothe- lial nitric oxide synthase genotype and ischemic heart disease. Circulation 2004;109:1359-65. [CrossRef]
Lembo G, De Luca N, Battagli C, Iovino G, Aretini A, Musicco M, et al. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid athero- sclerosis. Stroke 2001;32:735-40. [CrossRef]
Nagase S, Suzuki H, Wang Y, Kikuchi S, Hirayama A, Ueda A, et al. Association of eNOS gene polymorphisms with end stage renal diseases. Mol Cell Biochem 2003;244:113-8. [CrossRef]
Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, et al. Modifier effect of eNOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002;11:229-41. [CrossRef]
Schmıdt RJ, Yokota S, Tracy TS, Sorkın MI, Baylıs C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 1999:F794-7.
Hon WM, Lee JC, Lee KH. Effect of hemodialysis on plasma nitric oxide levels. Artif Organs 2000;24:387-90. [CrossRef]
Fayed HM, Kame MA, Sultan MM, Mowafy MN, Helmy SM, El-Zoghby MH. Nitric oxide generation by peripheral blood cells in chronic renal failure. Br J Biomed Sci 2002;59:24-9.
Rysz J, Luciak M, Kedziora J, Blaszczyk J, Sibinska E. Nitric oxide release in the peripheral blood during hemodialysis. Kid- ney Int 1997; 51: 294-300. [CrossRef]
Amore A, Bonaudo R, Ghigo D, Arese M, Costamagna C, Ciri- na P, et al. Enhanced production of nitric oxide by blood-dialysis membrane interaction. J Am Soc Nephrol 1995;6:1278-83.
Sasaki N, Kusano E, Ootomo T, Munakata M, Shimanuki K, Ando Y, et al. Bioincompatibility of hemodialysis membranes with special reference to the changes of blood IL-6, IL-8, and nitric oxide. J Jpn Soc Dial Ther 1999;32:363-8. [CrossRef]
Yılmaz E, Mir S, Berdeli A. Endothelial Nitric Oxide Synthase (eNOS) Gene Polymorphism in Early Term Chronic Allograft Nephropathy. Transplantation Proceedings 2009;41:4361-5. [CrossRef]
Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, et al. Association of eNOS Glu298Asp polymorphism with end- stage renal disease. Hypertension 2002;40:535-40. [CrossRef]
Spoto B, Benedetto FA, Testa A, Tripepi G, Mallamaci F, Maas R, et al. Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease. Am J Hypertens 2005;18:1549-55. [CrossRef]
Aras O, Hanson NQ, Bakanay SM, Tsai MY, Gulec S. Endothe- lial nitric oxide gene polymorphism (Glu298Asp) is not associ- ated with coronary artery disease in Turkish population. Thromb Haemost 2002;87:347-9.
Dellamea BS, Pinto LC, Leitão CB, Santos KG, Canani LH. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis. BMC Med Genet 2014;16:1-13. [CrossRef]
Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an en- dogenous inhibitor of nitric oxide synthase, is elevated in mon- keys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:1557-64. [CrossRef]
Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardio- vasc Pharmacol 1999;33:652-8. [CrossRef]
Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, et al. Asymmetric dimethylarginine plasma concen- trations differ in patients with endstage renal disease: relation- ship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998;53:1068-77. [CrossRef]
Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, et al. Physiology and biochemistry of endothe- lial function in children with chronic renal failure. Kidney Int 1997;52:468-72. [CrossRef]
Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-6.
Wahbi N, Dalton RN, Turner C, Denton M, Abbs I, Swamina- than R. Dimethylarginines in chronic renal failure. J Clin Pathol 2001;54:470-3. [CrossRef]
Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumu- lation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5. [CrossRef]
Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, et al. The GLU298ASP variant of nitric oxide synthase in- teracts with asymmetric dimethyl arginine in determining car- diovascular mortality in patients with end-stage renal disease. J Hypertens 2005;23:1825-30. [CrossRef]
Marson BP, Dickel S, Ishizawa MH, Metzger IF, Izidoro-Toledo T, da Costa BE, et al. Endothelial nitric oxide genotypes and haplo- types are not associated with end-stage renal disease. DNA Cell Biol 2011;30:55-9. [CrossRef]